clinical trial · NCT06419205
A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G
IgA NephropathyLupus Nephritis (LN)C3 (Complement Component 3) GlomerulopathyADX-097
brief summary
A Phase 2 Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Clinical Activity of ADX-097 Administered Subcutaneously in Male and Female Participants Aged 18 Years or Older With Immunoglobulin A Nephropathy (IgAN), Lupus Nephritis (LN), or Complement Component 3 Glomerulopathy (C3G)
started
Jun 27, 2024
primary completion
Jun 1, 2026
completion
Jun 1, 2026
last updated
Apr 20, 2025
official title
A Phase 2 Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Clinical Activity of ADX-097 Administered Subcutaneously in Male and Female Participants Aged 18 Years or Older With IgAN, LN, or C3G
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol